Status:
COMPLETED
Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State
Lead Sponsor:
Pfizer
Conditions:
Hepatitis C Virus
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will test two different formulations. The results will be used to select formulation for phase 3.
Eligibility Criteria
Inclusion
- Healthy volunteers.
Exclusion
- Standard for healthy volunteers.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00861458
Start Date
April 1 2009
End Date
June 1 2009
Last Update
July 8 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1070